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Confocal microscopyKv1.3 channels play an important role in modulating lymphocyte proliferation and apoptosis. We hypothe-
sized that Kv1.3 channels in B lymphocytes might be regulated by rituximab, an antibody to CD20, a drug
for treatments of B-cell lymphomas and autoimmune diseases. Using both whole-cell and cell-attached
patch-clamp techniques, we found that rituximab inhibited Kv1.3 channels in Daudi human B lymphoma
cells by promoting the channel inactivation at a concentration which was much greater than that required
for activation of CD20. The effect of rituximab on Kv1.3 channels was abolished after selective blockade of
FcγRIIB receptors with anti-FcγRIIB antibody. Western blot experiments showed that Daudi B cells expressed
both Kv1.3 channel and the low afﬁnity Fc receptor, FcγRIIB, which could be activated by the Fc region of
rituximab. In contrast, normal lymphocytes expressed less Kv1.3 channels with faster inactivation. Confocal
microscopy and ﬂow cytometry data showed that rituximab induced apoptosis of Daudi B cells and that
the effect was attenuated by blockade of FcγRIIB receptors and partially mimicked by inhibition of Kv1.3
channels. These results suggest that in addition to previously described complement-dependent cytotoxicity,
rituximab also induces apoptosis of malignant B lymphocyte by stimulating FcγRIIB receptors and inhibiting
Kv1.3 channels.
© 2011 Elsevier B.V. All rights reserved.1. Introduction
The non-Hodgkin's lymphomas rank ﬁfth in cancer incidence and
sixth in cancer mortality in the United States. Rituximab (Rituxan,
IDEC-C2B8), a chimeric mouse anti-human CD20 antibody, has been
used for the treatment of non-Hodgkin's lymphomas [9,25,33]. Several
lines of evidence suggest that the clinical outcomes of rituximab are
due to depletion of B cells via CD20-associated activation of
complement-dependent cytotoxicity [26,33,45], antibody-dependent
cellular cytotoxicity [6,21,30], or phagocytosis [7,40]. These events are
triggered by rituximab cross-linking of CD20molecules. The binding af-
ﬁnity of rituximab to CD20 is relatively high; it has been reported that
the Kd is less than 6 nM [12,14]. Since rituximab is a chimeric antibody
with human IgG1 Fc [19], the Fc region of rituximab also plays a very
critical role in mediating its cytotoxicity by ligation of Fc receptors on
the surface of nature killer cells [30] and macrophages [22]. Thelogy, Emory University School
0322, USA. Tel.: +1 404 727
rights reserved.constant serum concentration of rituximab in the patients treated
with a regular dose of 375 mg/m2 weekly for 4 weeks can reach
96.8 μg/ml (0.7 μM) [5], which could ligate any Fc receptors [24]. The
transient serumconcentration could be even higher. Since the low afﬁn-
ity FcγRIIB receptor is highly expressed on the surface of B cells [34] and
plays an important role in down-regulating immune responses
[17,20,29,37], rituximab may directly target B cells by stimulating this
receptor.
The Kv1.3 channel in B lymphocytes plays an important role in pro-
moting proliferation [28] and differentiation [43]. We have previously
shown that the Kv1.3 channel is expressed in Daudi B cells and has a
unique incomplete inactivation [44]. However, it remains largely un-
known how the Kv1.3 channel in B lymphocytes is regulated by the re-
ceptors on the surface of B cells and whether the incomplete
inactivation represents a unique gating of the Kv1.3 channel in malig-
nant Daudi B cells. Since CD20 can induce B cell apoptosis [36] and
Kv1.3 channel is regulated by the death receptor, Fas [39], we originally
hypothesized that cross-linking of CD20 with rituximab might result in
apoptosis of B cells not only via the pathways described previously
[1,10], but also through regulation of Kv1.3 channels. However, as de-
scribed above, the serum concentration of rituximab can reach levels
that could stimulate the low afﬁnity FcγRIIB receptor [5]. Among Fc re-
ceptors, the FcγRIIB receptor is the only Fc receptor which down-
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[17,20,29,37]. Therefore, it is also possible that rituximab regulates
Kv1.3 channels by stimulating the low afﬁnity FcγRIIB receptor. In the
present study, we show that rituximab inhibits Kv1.3 channels in
Daudi B cells by stimulating the FcγRIIB receptor and induces Daudi B
cells to undergo apoptosis partially through activation of FcγRIIB
receptors.
2. Materials and methods
2.1. Cell culture and patch-clamp techniques
Daudi B cell culture and patch-clamp experiments were per-
formed as we reported previously [41,44]. Freshly isolated human
lymphocytes were provided by Binli Tao (University of Alabama at
Birmingham).
2.2. Western blotting
Daudi B cell lysate (20 μg) was loaded and electrophoresed on 7.5%
SDS-PAGE gels (Mini-Protean® TGX™ Precast Gels, Bio-Rad) for 60 to
90 min. Gels were blotted onto nitrocellulose membranes for 1 h at
90 V. After 1 h blocking with 5%milk in TBS-T buffer, PVDF membranes
were incubated with primary antibody (1:1000 dilution) of either goat
anti-human FcγRIIB polyclonal antibody (R&B, systems) or rabbit anti-
human Kv1.3 antibody (Alomone Labs) overnight at 4 °C, and then re-
spectively incubated with ReserveAP™ phosphatase-conjugated rabbit
anti-goat or goat anti-rabbit IgG secondary antibody (1:5000 dilution,
KPL) for 1 h after 3 vigorous washes. Blots were developed by chemilu-
minescence using ECL Plus Western Blotting Detection System (GE
healthcare).
2.3. Confocal microscopy imaging and ﬂow cytometry analysis
To evaluate apoptosis, Daudi B cells were stained with both FITC-
conjugated annexin V (AV) and propidium iodide (PI). Confocalmicros-
copy experiments were performed to determine whether and how
rituximab induces apoptosis in Daudi B cells. The cell membrane of ap-
optotic cells was stained with AV because phosphatidylserine, a lipid
which has a high binding afﬁnity to AV, is externalized in apoptotic
cells. The nuclei of apoptotic cells were stained with PI because the nu-
clear membrane of apoptotic cells becomes permeable to PI. AVwas ex-
cited with 488 nm laser and visualized through a 515 nm emission
ﬁlter, shown in green. PI was excited with 488 nm laser and visualized
through a 590 nm emission ﬁlter, shown in red. In each set of experi-
ments, images were taken using the same parameter settings. To quan-
tify the number of apoptotic cells, the percentages of apoptotic cells, as
determined by AV- and PI-positive cells, were measured on a FACScali-
bur ﬂow cytometer (Becton Dickinson) within 30 min. AV and PI were
excited with 488 nm laser. The emissions were detected through either
a 515 nm ﬁlter for AV or a 580 nm ﬁlter for PI.
2.4. Chemicals and solutions
Most chemicals were obtained from Sigma Chemical Co. Rituximab
was provided by Dr. Mansoor N. Saleh (University of Alabama at
Birmingham, Birmingham, Alabama, USA). Goat anti-human FcγRIIB
antibody was purchased from R&D Systems. NaCl (or KCl) bath solution
contained (in mM): 145 NaCl (or 145 KCl), 5 KCl (or 5 NaCl), 1 CaCl2, 1
MgCl2, and 10 N-hydroxyethylpiperazine-N′-2-ethanesulfonic acid
(HEPES), at a pH of 7.4. KCl (or NaCl) pipette solution contained (in
mM): 145 KCl (or 145 NaCl), 50 nM free Ca2+ (after titration with
2 mM ethylene glycol-bis(b-aminoethyl ether)-N,N,N′,N′-tetraacetic
acid), 1 MgCl2, 2 Na2-ATP (or 2 K2-ATP), and 10 HEPES, at a pH of 7.2.
All the concentrations throughout this article are shown as the ﬁnal
concentration.2.5. Statistical analysis
Paired-t test was used for the comparison between two groups of
data from the same patch-clamp recording before and after experi-
mental manipulations. Student's t test was used for the comparison
between two groups of data from two separate patch-clamp record-
ings. The analysis of variance for multiple comparisons was used for
the comparison among multiple groups of data. Data are shown as
mean±SD. pb0.05 is considered statistically signiﬁcant.
3. Results
3.1. The gating and expression of Kv1.3 channels are upregulated in
Daudi cells
Our previous report showed that Kv1.3 channel was expressed in
Daudi B cells and that the channel could not inactivate completely in re-
sponse to prolonged depolarization [44]. Consistent with our previous
ﬁnding, the present study showed that depolarizing voltage-step pulses
induced outward currentswhich did not inactivate completely, butwere
almost completely blocked with 10 nM MgTX, a selective blocker for
Kv1.3 and Kv1.2 channels (Fig. 1A). Since we previously showed that
the current was almost abolished with antisense to Kv1.3 channel [44],
we concluded that this current resulted from activation of Kv1.3 chan-
nels. To determine whether the incomplete inactivation represents the
unique gating of Kv1.3 channel in malignant Daudi B cells, the whole-
cell recording was also established in normal human lymphocytes. An
outward current was also observed in these lymphocytes. Compared to
the Kv1.3 currents in Daudi cells, the Kv1.3 currents in normal lympho-
cytes were much smaller and inactivate completely (Fig. 1B). Therefore,
the decay rate of the currents induced by a voltage-step pulse from the
holding potential of −60 mV to +60 mV was analyzed and compared
between Daudi and normal lymphocytes. The representative Kv1.3 cur-
rents induced by a voltage-step pulse from a holding potential of
−60 mV to +60 mV in either a Daudi cells or a normal lymphocyte
were ﬁtted nicely with a single exponential function, as shown in
Fig. 1C. The summarized inactivation time constant was 509.8±
51.2 ms from 6 individual Daudi cells and 347.3±35.4 ms from 6 indi-
vidual normal lymphocytes (Fig. 1D).Western blot experiments showed
that in contrast to Daudi B cells, normal lymphocytes expressed less
Kv1.3 channels (Fig. 1E). These data suggest that the gating and expres-
sion of Kv1.3 channels are upregulated in malignant Daudi B cells. How-
ever, it remains to be determined whether the upregulation of Kv1.3
channels is related to the malignancy of Daudi B cells.
3.2. Rituximab promotes inactivation of Kv1.3 channels via FcγRIIB
receptors
To examine the effect of rituximab on Kv1.3 channel gating, Kv1.3
currents induced by a voltage-step protocol before and after applica-
tion of rituximab were recorded as shown in Fig. 2A. Rituximab
seemed to reduce the current amplitude by promoting the channel
inactivation. Therefore, the decay rate of the current induced by a
voltage-step pulse from the holding potential of −60 mV to
+60 mV before rituximab was compared with that after rituximab.
Fig. 2C showed that the representative currents before and 3 min
after 100 μg/ml rituximab were ﬁtted nicely with a single exponential
function. After application of rituximab, the mean inactivation time
constant (τ) was signiﬁcantly reduced, from 517.3±54.6 ms to
169.0±26.1 ms (pb0.001; n=6) (Fig. 2E). However, in the cells pre-
treated with 2 μg/ml anti-FcγRIIB antibody to block the FcγRIIB re-
ceptor, rituximab no longer affected Kv1.3 currents (Fig. 2B). Fig. 2D
showed that the representative currents induced by a voltage-step
pulse from the holding potential of −60 mV to +60 mV before and
3 min after 100 μg/ml rituximab in these pretreated cells were ﬁtted
well with a single exponential function. The mean inactivation time
Fig. 1. Kv1.3 inactivation and expression are different between Daudi cells and normal lymphocytes. (A) Representative whole-cell recordings from a Daudi cell before (left) and
after application of 10 nM MgTX to the bath (right). (B) Representative whole-cell recordings from a normal lymphocyte before (left) and after application of 10 nM MgTX to the
bath (right). (C) Representative Kv1.3 currents (black lines behind red and green line) induced by a voltage-step pulse from the holding potential of −60 mV to +60 mV were
ﬁtted with a single exponential function, yielding a time constant (τ) of either 511.0 ms in a Daudi cell (red line) or 314.7 ms in a normal lymphocyte (green line). (D) Summary
plot of τ in either Daudi cells (open bar) or normal lymphocyte (solid bar). (E) Western blot of Daudi cells (lane 1) and normal lymphocytes (lane 2), showing that Daudi cells
express higher levels of Kv1.3 channels than normal lymphocytes. Detection of β-actin was used to show equal loading of protein in each lane. The data represent three individual
experiments showing consistent results. In (A) and (B), a voltage-step protocol from−100 mV to +60 mV with an increment of +20 mV at the holding potential of−60 mV was
used to induce Kv1.3 current. Patch pipettes were ﬁlled with KCl pipette solution while NaCl bath solution was used for the bath. No leaky subtraction was applied to this ﬁgure and
any other patch-clamp recordings.
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485.8±47.8 ms (after rituximab) (p=0.129; n=6) (Fig. 2E). To con-
ﬁrm the involvement of the FcγRIIB receptor, we performed Western
blotting experiments. The data showed that the FcγRIIB receptor is
expressed in Daudi B cells (Fig. 2F). To examine the effect of rituxi-
mab on Kv1.3 channel at the single-channel level, we also performed
cell-attached patch-clamp recordings. Consistent with our previous
report [44], a 19-pS Kv channel was observed in Daudi cells and did
not completely inactivate in response to prolonged depolarization
(Fig. 3A). Like Kv1.3 whole-cell currents, the single-channel activity
was completely blocked with 10 nM MgTX in the patch pipette
(Fig. 3B). Fig. 3C showed that at 5 min after application of 100 μg/ml
rituximab to the bath, the single-channel events were almost only ob-
served during the initial second, indicating that rituximab promotes
Kv1.3 channel inactivation. However, the unit conductance was
unchanged (19.5±0.6 pS) (p=0.694, n=4), compared to that be-
fore rituximab (19.4±0.9 pS). The effect of rituximab on Kv1.3 chan-
nel inactivation was abolished in the cells pretreated with 2 μg/ml
anti-FcγRIIB antibody to selectively block the FcγRIIB receptor
(Fig. 3D). These data suggest that rituximab promotes Kv1.3 channel
inactivation via the FcγRIIB receptor.
3.3. Kv1.3 channel in Daudi cells can be activated by a slow
depolarization
Since lymphocytes are not excitable cells, the membrane potential
may alter gradually. To determine whether a slow depolarization acti-
vates Kv1.3 channel, a voltage-ramp protocol was used to quickly getthe I–V relationship. The voltage-ramp protocol from −120 to
+60 mV with the holding potential of −60 mV was given at a rate of
1 min. A voltage-dependent outward current was induced by the
voltage-ramp protocol. The threshold potential for activation of this
current was approximately −40 mV. This current was completely
blocked by addition of 100 μM quinine, a generic K+ channel blocker,
to the bath in all of 11 recordings. The blockade was almost completely
reversed every timewhen quininewaswashed out of the bath (Fig. 4A).
The current was also blocked by addition of either 100 nM charybdo-
toxin (ChTX), a voltage-dependent K+ channel blocker, to the bath in
all of 8 recordings, or 10 nM margatoxin (MgTX), a Kv1.3 channel
blocker, to the bath in all of 6 recordings. The blockade by quinine
was completely reversible while the blockade by ChTX orMgTXwas ei-
ther partially reversible or irreversible. This is consistent with the fact
that MgTX has a slow dissociation rate [15]. Replacement of 145 mM
Na+ in the bath with 145 mM K+ shifted the reversal potential to
0 mV (Fig. 4B), indicating that this current is carried by K+. Further-
more, the replacement of cytoplasmic K+ with 145 mM Na+ by
whole-cell dialysis of the cell eliminated the K+ current. These data to-
gether with our previous report [44] suggest that a slow depolarization
can also activate Kv1.3 channels in Daudi B cells.
3.4. Rituximab inhibits Kv1.3 currents induced by a slow depolarization
via activation of FcγRIIB receptors
To determine how rituximab affects Kv1.3 currents in response to
a slow membrane depolarization, the voltage-ramp protocol was also
used in the following experiments. Since rituximab cross-links CD20
Fig. 2. Rituximab promotes Kv1.3 channel inactivation inDaudi cells via FcγRIIB receptors. (A) Representativewhole-cell recordings from aDaudi cell before (left) and after application of
100 μg/ml rituximab to the bath (right). (B) Representative whole-cell recordings from a Daudi cell pretreatedwith 2 μg/ml goat anti-human FcγRIIB antibody for 5 min before (left) and
after application of 100 μg/ml rituximab to the bath (right). (C) Representative Kv1.3 currents (black lines behind red and green line) induced by a voltage-step pulse from the holding
potential of−60 mV to +60mV in a control Daudi cells were ﬁtted with a single exponential function, yielding a time constant (τ) of either 529.2 ms under control conditions before
rituximab (red line) or 135.9 ms after application of 100 μg/ml rituximab to the bath (green line). (D) Representative Kv1.3 currents induced by a voltage-step pulse from the holding
potential of−60 mV to+60 mV in a Daudi cells pretreatedwith 2 μg/ml goat anti-human FcγRIIB antibody for 5 minwere ﬁttedwith a single exponential function, yielding a time con-
stant (τ) of either 497.1 ms under control conditions before rituximab (red line) or 486.3 ms after application of 100 μg/ml rituximab to the bath (green line). (E) Summary plot of τ either
in control Daudi cells (left bars) or Daudi cells pretreatedwith 2 μg/ml goat anti-human FcγRIIB antibody for 5 min (right bars). (F)Western blot shows that FcγRIIB is expressed inDaudi
B cells. The voltage-step protocol and solutions were the same as used in Fig. 1.
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ﬁrst exposed Daudi B cells to rituximab at 10 μg/ml (=69 nM), a con-
centration which was over 10 times greater than the Kd for rituximab
to bind to CD20. However, the data from our whole-cell patch-clamp
experiments demonstrated that at this concentration rituximab failed
to regulate Kv1.3 channels in Daudi B cells (Fig. 5A). But at a high con-
centration (200 μg/ml=1.4 μM) which can stimulate the low afﬁnity
Fc receptors (Kd is 0.6–2.5 μM, [24]), rituximab signiﬁcantly reduced
Kv1.3 whole-cell currents within 2 min after it was added to the
bath (Fig. 5B). We hypothesized that rituximab may stimulate the
low afﬁnity FcγRIIB receptor which is highly expressed on the surface
of B cells [34]. Since anti-FcγRIIB antibody can be used for selectively
blocking FcγRIIB receptors [11], Daudi B cells were pretreated with
2 μg/ml goat anti-human FcγRIIB antibody to selectively block the
FcγRIIB receptor on Daudi cells. After the pretreatment, application
of 200 μg/ml rituximab to the bath no longer reduced Kv1.3 currents
(Fig. 5C). Compared to rituximab which has a human IgG1 Fc region
[19], rabbit IgG should hardly bind to human Fc receptors on Daudi
cells. Therefore, rabbit IgG was used as a control. Kv1.3 currents in
Daudi B cells were only slightly reduced at 3 min after addition of
200 μg/ml rabbit IgG to the bath (Fig. 5D). Percent inhibition of the
peak Kv1.3 currents under each condition was plotted in Fig. 5E.
10 μg/ml rituximab did not alter the peak Kv1.3 current during the
3-min period in 8 whole-cell recordings (p>0.05, n=8). However,
200 μg/ml rituximab reduced the peak Kv1.3 current by more than
70% within 2 min (pb0.001, n=9). In contrast, in Daudi B cells pre-
treated with 2 μg/ml anti-FcγRIIB antibody, 200 μg/ml rituximab
failed to reduce Kv1.3 currents (p>0.05, n=8). As a control,
200 μg/ml rabbit IgG tended to reduce Kv1.3 currents in Daudi Bcells at 3 min after the addition, but the effect is only marginally sig-
niﬁcant (p=0.05, n=7).
To examine the concentration-dependent effects of rituximab, ﬁve
concentrations of rituximab (12.5, 25, 50, 100, and 200 μg/ml) were
used in 6 whole-cell recordings. The representative recordings of Kv1.3
currents before and at 1, 2, and 3 min after addition of 12.5, 50, or
200 μg/ml rituximabwere plotted in Fig. 6A. As shown in Fig. 6B, the per-
centages of Kv1.3 current inhibition versus rituximab concentrations
were ﬁtted with the Hill function; the IC50 for rituximab to inhibit
Kv1.3 currentwas 80 μg/ml. These results suggest that the effect of ritux-
imab on Kv1.3 channels is dependent on the activity of the low afﬁnity Fc
receptor FcγRIIB rather than the high afﬁnity B cell surfacemarker CD20.
The present study for the ﬁrst time suggests that the Kv1.3 channel in B
lymphocytes is regulated by the FcγRIIB receptor. However, the underly-
ing signal transduction pathway remains to be determined.
3.5. Rituximab reduces the membrane potential of Daudi B cells via
FcγRIIB receptor inhibition of Kv1.3 channels
We have shown that Kv1.3 channels play an important role in reg-
ulating the membrane potential of Daudi B cells [44]. Since rituximab
could inhibit Kv1.3 channels, theoretically, the membrane potential of
Daudi B cells should be reduced after application of rituximab. There-
fore, after forming the whole-cell conﬁguration, the membrane po-
tential of Daudi B cells was measured with the current-clamp mode
when the current was clamped at zero. The data showed that applica-
tion of 100 μg/ml rituximab signiﬁcantly reduced the membrane po-
tential from −48.6±4.4 mV to −37.7±5.4 mV (pb0.001, n=6)
when Daudi B cells were under control conditions (Fig. 7). In contrast,
Fig. 3. Rituximab promotes Kv1.3 channel inactivation in Daudi cells via FcγRIIB receptors in cell-attached patches. (A) 5 superimposed single-channel currents from 3 cell-attached
recordings show that a voltage-step pulse from 0 mV to +80 mV (–Vpipette) induced Kv1.3 channel activity which does not inactivate completely. (B) 5 superimposed single-
channel currents from 5 cell-attached recordings show that Kv1.3 channel activity was completely blocked by 10 nM MgTX in the patch pipette. (C) 5 superimposed single-
channel currents from 4 cell-attached recordings either before (left) or after addition of 100 μg/ml rituximab to the bath (right) show that rituximab promoted the channel inac-
tivation. (D) 5 superimposed single-channel currents from 5 cell-attached recordings in Daudi cells pretreated with 2 μg/ml goat anti-human FcγRIIB antibody for 5 min show that
blockade of FcγRIIB receptor abolished the effect of rituximab. Inset panels A1, B1, C1, C2, or D1 shows a representative trace in each superimposed traces. A voltage-step pulse from
a holding potential of 0 mV to +80 mV (–Vpipette=+80 mV). NaCl bath solution was used both for ﬁlling patch pipettes and for the bath.
Fig. 4. Kv1.3 channel is induced by a slow voltage-ramp pulse. (A) Addition of 100 μM quinine (upper left), 100 nM ChTX, a voltage-dependent K+ channel blocker (upper right), or
10 nM MgTX, a Kv1.3 channel blocker (supper left), to the bath completely blocked whole-cell currents induced by a voltage-ramp protocol. Immediately after the blockade was
observed, ChTX and MgTX were washed out of the bath. The blockade by ChTX was almost completely reversed in 1 out of total 8 recordings (trace c, upper right), but was partially
reversed in the other 7 recordings. The blockade by MgTX was partially reversed in 2 out of total 6 recordings (trace c, supper left) or irreversible in the other 4 recordings. (B) The
ChTX-sensitive, voltage-dependent current was reversed by replacement of 145 mM Na+ in the bath with 145 mM K+; the reversal potential was shifted to 0 mV (left), and dis-
appeared after whole-cell dialysis of the cells with 145 mM Na+ (right). A voltage-ramp protocol was used to induce the voltage-dependent Kv1.3 currents, in which the voltage
immediately went down to−120 mV from a holding potential of−60 mV and then gradually went up to +60 mV. As indicated, patch pipettes were ﬁlled with either KCl pipette
solution containing 145 mM K+ or NaCl pipette solution containing 145 mM Na+; the bath was washed with either KCl bath solution or NaCl bath solution. Upward tracings show
outward currents, representing K+ efﬂux.
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Fig. 5. Rituximab reduces Kv1.3 currents induced by a slow voltage-ramp pulse in an FcγRIIB receptor-dependent manner. (A) Representative whole-cell Kv1.3 currents induced by
a voltage-ramp protocol; the protocol was given at a rate of 1 min. After the ﬁrst recording (before) was made, 10 μg/ml rituximab was added to the bath. Then, the voltage-ramp
protocol was given to the cell for additional three times, respectively at 1, 2, or 3 min after rituximab. The four current traces in response to the voltage-ramp protocol were super-
imposed and showed no changes. (B) A remarkable decrease in Kv1.3 currents occurred at 2 and 3 min after addition of 200 μg/ml rituximab to the bath. (C) 200 μg/ml rituximab
failed to reduce Kv1.3 currents in a Daudi B cell pretreated with 2 μg/ml goat anti human FcγRIIB antibody to selectively block FcγRIIB receptors. (D) Addition of 200 μg/ml rabbit
IgG to the bath slightly reduced Kv1.3 currents only at 3 min after the addition. (E) Summary plots of relative inhibition of the peak Kv1.3 currents under the conditions used in A
through D. Patch pipettes were ﬁlled with KCl pipette solution while NaCl bath solution was used for the bath.
510 L.-H. Wang et al. / Biochimica et Biophysica Acta 1823 (2012) 505–513when Daudi B cells were pretreated with 2 μg/ml anti-FcγRIIB anti-
body to selectively block the FcγRIIB receptor, application of 100 μg/
ml rituximab no longer affected the membrane potential, −48.5±
5.0 mV versus −48.2±4.8 mV (p=0.679, n=6). Application of
10 nM MgTX to the bath strongly reduced the membrane potentialFig. 6. Rituximab inhibits Kv1.3 currents in a dose-dependent manner. (A) Representative
before and 1, 2, or 3 min after addition of rituximab to the bath at 12.5 (left), 50 (middle)
12.5, 25, 50, 100, or 200 μg/ml rituximab was added to the bath (solid circles). Data are sh
solution was used for the bath.from −49.2±4.5 mV to −9.2±3.4 mV (pb0.001, n=6), but in the
presence of MgTX, 100 μg/ml rituximab did not further reduce the
membrane potential (−9.2±3.4 mV; p=0.695, n=6). These data
suggest that rituximab reduces the membrane potential of Daudi B
cells by inhibiting Kv1.3 channels through the FcγRIIB receptor.recordings of Kv1.3 currents. Four traces were superimposed showing Kv1.3 currents
or 200 μg/ml (right). (B) Relative inhibition of the peak Kv1.3 currents at 3 min after
own as mean±SD. Patch pipettes were ﬁlled with KCl pipette solution while NaCl bath
Fig. 7. Rituximab reduces the membrane potential of Daudi B cells via FcγRIIB receptor
inhibition of Kv1.3 channels. The experiments were performed either under control
conditions or after pretreatment with 2 μg/ml goat anti-human FcγRIIB antibody for
5 min. Left bars show that rituximab reduced the membrane potential in control
Daudi B cells. Middle bars show that rituximab did not alter the membrane potential
in Daudi B cells pretreated with 2 μg/ml goat anti-human FcγRIIB antibody for 5 min.
Right bars show that MgTX reduced the membrane potentials in control Daudi B cells
and that after MgTX, rituximab did not further reduce the membrane potential. The
membrane potential from the same whole-cell recording before MgTX or rituximab
(open bars) was used as its own control for comparison with those 5 min after applica-
tion of either 10 nM MgTX (black bars) or rituximab (gray bars). Membrane potentials
of Daudi cells were measured using the current-clamp mode (I=0).
511L.-H. Wang et al. / Biochimica et Biophysica Acta 1823 (2012) 505–5133.6. Rituximab induces apoptosis of Daudi B cells partially via FcγRIIB
receptors
Recent studies have shown that the FcγRIIB receptor plays a role
in mediating antibody-induced apoptosis of malignant B cells [27].
To determine whether the FcγRIIB receptor acts as one of the path-
ways for rituximab to induce apoptosis, Daudi B cells were stained
with FITC-conjugated annexin-V (AV) and propidium iodide (PI).
First, confocal microscopy experiments were performed, as shown
in Fig. 8A. In untreated Daudi cells, only occasionally we could see
AV- and PI-positive cells (apoptotic cells). In contrast, in the cells
treated with 200 μg/ml rituximab for 30 min, a signiﬁcant portion of
cells underwent apoptosis. In a parallel with the inhibition of Kv1.3
channels observed in patch-clamp experiments, pretreatment of the
cells with 2 μg/ml anti-FcγRIIB antibody attenuated the rituximab-
induced apoptosis. To determine whether inhibition of Kv1.3 chan-
nels by Kv1.3 channel blockers could result in apoptosis, Daudi B
cells were treated with 10 nM MgTX for 30 min. MgTX seemed to in-
duce a portion of cells to undergo apoptosis. To quantify these effects,
we performed six separate ﬂow cytometry experiments for each
group. The representative data were shown in Fig. 8B. The summa-
rized results were plotted in Fig. 8C. Under control conditions, only
3±1% (mean±SD, n=6) cells were automatically apoptotic. In con-
trast, after the cells were treated with 200 μg/ml rituximab for
30 min, the number of apoptotic cells was increased to 24%±6%
(pb0.001, n=6). This effect was attenuated in the cells pretreated
with 2 μg/ml anti-FcγRIIB antibody to selectively block the FcγRIIB re-
ceptor; the number of apoptotic cells was 14±5%, which is signiﬁ-
cantly less than that in the cells treated with rituximab alone
(pb0.001, n=6), but still greater than that in the cells under control
conditions (pb0.001). This indicates that rituximab induces apoptosis
through the FcγRIIB receptor, but the FcγRIIB receptor should not be
the only pathway for rituximab-induced apoptosis. After the cells
were treated with 10 nM MgTX for 30 min, the number of apoptotic
cells was increased to 8%±3% (pb0.001, n=6), but less than that
in the cells treated with rituximab (pb0.001). These data suggest
that a high concentration of rituximab could induce apoptosis of
Daudi B cells partially by stimulating the FcγRIIB receptor and thatinhibition of Kv1.3 channels may contribute to the rituximab-
induced apoptosis of B cells.
4. Discussion
We have previously shown that Kv1.3 channel is expressed in
Daudi B cells and does not inactivate completely in response to pro-
longed depolarization [44]. The present study shows that the expres-
sion levels of Kv1.3 channel in Daudi B cells are higher than those in
normal lymphocytes and that unlike the Kv1.3 channel in Daudi B
cells, the Kv1.3 channel in normal lymphocytes does inactivate
completely. However, it is unlikely that defective inactivation and en-
hanced expression of Kv1.3 channels account for the malignant prolif-
eration of Daudi B cells, because our recent studies suggest that an
intermediate Ca2+-activated K+ channel rather than Kv1.3 channel
promotes Daudi cell proliferation [41]. It has been suggested that
Kv1.3 channel plays an important role in regulating apoptosis in T
cells [39]. The present study shows that Kv1.3 channel is downregu-
lated by the anti-lymphoma drug, rituximab and that the downregu-
lation appears to contribute to rituximab-induced apoptosis. These
studies together suggest that the incomplete inactivation and the en-
hanced expression of Kv1.3 channel observed in this study may be
more important for Daudi B cells to escape from apoptosis rather
than to become highly proliferative. Crosslinking of the CD20 receptor
with its antibodies including rituximab could induce apoptosis of ma-
lignant B cells [16,36]. However, our results shows that rituximab in-
hibits Kv1.3 channel with an IC50 of 80 μg/ml (552 nM), which is
almost 100 times higher than the Kd (6 nM) for rituximab to bind to
CD20 [12], indicating that the effect is not mediated by the CD20 re-
ceptor. Since the Kd for IgG to stimulate the low afﬁnity Fc receptors
is in the range from 0.6 to 2.5 μM [24] and the FcγRIIB receptor is
expressed in Daudi B cells, rituximab should activate the FcγRIIB re-
ceptor. Indeed, we show that selective blockade of the FcγRIIB recep-
tor with its antibody is able to abolish the inhibition of Kv1.3 channels
by rituximab. These results for the ﬁrst time suggest that the Kv1.3
channel in B lymphocytes is regulated by the FcγRIIB receptor.
Recent studies suggest that the Kv1.3 channel in T lymphocytes
acts as a therapeutic target for treatments of autoimmune diseases
[2,35] such as type-1 diabetes mellitus or rheumatoid arthritis [4]
and multiple sclerosis [3,31,42]. Since the FcγRIIB receptor plays an
important role in down-regulating immune responses in B lympho-
cytes [17,20,29,37], inhibition of Kv1.3 channels by activation of the
FcγRIIB receptor may complement the possible clinical use of Kv1.3
channel blockers to treat autoimmune diseases. Our results show
that rituximab strongly inhibits Kv1.3 channels in B cells and induces
apoptosis by stimulating the FcγRIIB receptor with its human Fc re-
gion. Therefore, in addition to the previously described
complement-dependent cytotoxicity [26,33,45], antibody-dependent
cytotoxicity [6,21,30], or phagocytosis [7,40], rituximab may directly
target B cells by stimulating an FcγRIIB receptor-dependent pathway
associated with inhibition of Kv1.3 channels. Although crosslinking of
CD20 does serve a pathway for rituximab and other anti-CD20 anti-
bodies to induce B cell apoptosis, CD20 antibodies alone at a concen-
tration (10 μg/ml) which could cross-link CD20 molecules are unable
to produce the effect unless a secondary antibody is present to further
cross-link the CD20 antibodies [16,36]. Since the serum concentration
of rituximab in the patients can reach 96.8 μg/ml (0.7 μM) [5], rituxi-
mab should not only stimulate CD20, but also activate the low afﬁnity
FcγRIIB receptor. The present in vitro study shows that rituximab di-
rectly induces apoptosis of cultured Daudi cells by stimulating the
FcγRIIB receptor. However, the FcγRIIB receptor is also expressed in
monocytes, macrophages, and some natural killer cells [13,18,38].
The FcγRIIB receptor in these effector cells negatively modulates
antibody-dependent cytotoxicity against melanoma and breast
tumor [8]. The FcγRIIB receptor may reduce clinical efﬁcacy of ritux-
imab by promoting its internalization [23]. Nevertheless,
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Fig. 8. Blockade of FcγRIIB receptors attenuates rituximab-induced apoptosis of Daudi B cells. (A) Representative confocal microscopy data showed that 200 μg/ml rituximab induced
apoptosis of Daudi B cells in both FcγRIIB receptor- and Kv1.3 channel-dependent manner. Apoptotic cells were stained with FITC-conjugated Annexin V (shown in green, upper left
panels in each image) due to phosphatidylserine externalization and propidium iodide (shown in red, upper rights in each image) due to permeable nuclear membrane. DIC images
were taken to show the total Daudi cells in the ﬁeld (lower left panels in each image). Lower right panels in each image show the overlay of AV, PI and DIC images. (B) Representative
ﬂow cytometry data showed that 200 μg/ml rituximab increased the number of apoptotic cells in an FcγRIIB receptor-dependent manner. In lower left gate, cells were both AV- and
PI-negative; in lower right gate, cells were AV-positive; in the upper left gate, cells were PI-positive; in the upper right gate, cells were both AV- and PI-positive. The experiments
were performed in the cells under the conditions used for the confocal microscopy experiments. (C) Summary plots of percent apoptotic cells under each condition from six separate
ﬂow cytometry experiments, showing that 200 μg/ml rituximab signiﬁcantly increased the number of apoptotic cells partially through FcγRIIB receptors and Kv1.3 channels. As indicated,
Daudi B cells were under control conditions, treated with 200 μg/ml rituximab for 30 min either without or with pretreatment with 2 μg/ml goat anti-human FcγRIIB antibody for 5 min,
or treated with 10 nMMgTX for 30 min.
512 L.-H. Wang et al. / Biochimica et Biophysica Acta 1823 (2012) 505–513controversial results also exist, showing that the FcγRIIB receptor
may be a target of monoclonal antibody therapy of B-cell lymphoma
[32]. In addition, the present study indicates that the FcγRIIB receptor
may contribute to the multiple pathways initiated by rituximab for
depleting B cells. Therefore, the role of the FcγRIIB receptor in anti-
lymphoma effect of rituximab remains to be determined.
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